Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%

Truist set an $83 price target on Viking Therapeutics, implying 188% upside from the June 8 opening price of $28.75. The company’s VK2735 obesity drug is in phase 3 for the injectable form, with the oral version expected to enter phase 3 in Q3 2026, but Viking remains pre-revenue and reported a $109 million net loss in 2024 that widened to $359 million in 2025. The bullish thesis is driven by a potential $150 billion obesity-drug market by 2035, offset by significant clinical and execution risk.

Analysis

The setup is less about one analyst’s target and more about a binary re-rating path: VKTX is now being valued on probability-weighted optionality across two formulations, which can create asymmetric upside into each clinical milestone. In crowded obesity, differentiation is not just efficacy; tolerability and dosing convenience are the true economic moats because they drive persistence, refill rates, and ultimately payer acceptance. If VK2735 can show competitive weight-loss with fewer discontinuations, the market may assign it a platform multiple rather than a single-asset binary.

The second-order effect is that every credible GLP-1 contender increases pressure on the incumbents to defend access and formulary share, especially if a new entrant is perceived as either cheaper to manufacture or easier to dose. That matters because the obesity franchise is likely to bifurcate into premium, highly persistent drugs and a lower-price tier for broader utilization; VKTX only needs to win a meaningful slice of the premium tier to justify a much higher valuation, but it will not get there without clean phase 3 data and a believable commercial path. The oral version is the real inflection point if it can reduce administration friction, though it also carries a higher failure risk and a longer timeline, so the market may over-assign near-term value to a catalyst that is still 12+ months away.

The key contrarian point is that the stock’s upside is already being pulled forward by obesity TAM narratives while the real valuation hazard is financing dilution before commercialization. With burn running ahead of cash generation and no revenue buffer, any trial delay or modest efficacy miss could compress the equity fast, because the market will reprice not only pipeline probability but also the cost of extending runway. In other words, VKTX is a volatility asset masquerading as a growth story: the nearer-term trade is on catalyst compression, not on long-duration fundamentals.

Key Decisions for Investors

• Buy VKTX only as a catalyst trade into phase 3 readouts; size small and treat it as a binary event position, not a core healthcare long. Best risk/reward is entering on post-news pullbacks rather than chasing strength.
• Express a relative-value view via long VKTX / short a basket of crowded obesity incumbents on a 3-6 month horizon if you want exposure to pipeline upside without paying full franchise multiples. The trade works if VKTX is perceived as a differentiated tolerability story.
• Use options instead of common equity: call spreads in VKTX for the next major data window to cap downside from dilution or trial noise while preserving upside convexity. This is preferable given the stock’s implied volatility and financing risk.
• Fade the move if VKTX rallies sharply before phase 3 data; take profits on strength and wait for execution proof. The market may be discounting an approval path that is still several readouts away.
• Avoid shorting outright unless you can tolerate squeeze risk; the better bearish expression is a put spread after a sharp run-up or into any gap higher on speculative commentary.